

VAKSIMUNE®
IBD M+

PROTECTION AGAINST
INFECTIOUS BURSAL DISEASE

vaksindo
Research Based Vaccine

VAKSIMUNE® IBD M+

Challenges & Our Commitment:

Infectious Bursal Disease (IBD), or Gumboro, is a highly contagious viral infection affecting young chickens. The virus attacks the bursa of Fabricius, leading to severe immunosuppression, reduced productivity, and significant economic losses. Transmission occurs easily through direct contact or contaminated feed, water, and equipment, with young birds being the most vulnerable.

VAKSIMUNE® IBD M+ addresses these challenges with a clear advantage: its high maternal antibody breakthrough capacity (750–1000). As an intermediate plus vaccine containing the Moulthrop strain, it reliably induces protective immunity even under strong maternal antibody levels, a critical hurdle in field conditions. Field and farm trials confirm its safety and efficacy, with high antibody titers, 100% protection against vvIBD challenge, ensuring flock health is maintained

Features:

VAKSIMUNE® IBD M+ is a Freeze dried modified live virus, each dose contains :

IBD virus Moulthrop strain > $10^{3.0}$ EID_{50}

VAKSIMUNE® IBD M+ is propagated in embryonated Specific Pathogen Free (SPF) chicken eggs. Maternal Antibody Breakthrough is 750-1000.



Vaccination Strategy for breeder/layer/broiler:
1st Vaccination : 11-14 Days of Age
2nd Vaccination : 18-21 Days of Age

Vaccine Administration :
Vaccine can be administered via oral drop or drinking water

Packing size:
Available in 1000 & 2000 Doses

VAKSIMUNE® IBD M+ Benefits

High Maternal Antibody (MDA) Breakthrough


VAKSIMUNE® IBD M+ is specially developed to break through high maternal antibody levels (750–1000), ensuring early colonization of the bursa and rapid immune stimulation even under strong MDA conditions.


Supports Healthy Immune Function

VAKSIMUNE® IBD M+ stimulates strong protection while preserving the bursa's vital role in immunity. It allows birds to mount effective responses to other vaccines, ensuring comprehensive disease protection without compromising immune competence.

Superior Serological Response

Field trials consistently show that VAKSIMUNE® IBD M+ achieves stronger and longer-lasting antibody responses compared to Immunecomplex and other intermediate plus vaccines, delivering reliable and durable protection.





Superior Antibody Response with Vaksimune® IBD M+

VAKSIMUNE® IBD M+ delivers a clear advantage over Immunecomplex and other intermediate plus vaccines, particularly during the critical window of day 23 to day 28. The higher antibody titers observed in this period are the result of early colonization of the bursa and strong viral replication, allowing the vaccine to stimulate faster and more effective immunity. This early and robust protection is crucial for securing flock health during their most vulnerable stage, ensuring consistent performance and reliable disease control.

Maintains Immune Competence

VAKSIMUNE® IBD M+ protects against IBD without damaging the bursa of Fabricius. The vaccine does not impair the bursa's ability to support immunity, nor does it induce mortality. As shown by the ND titer profile, birds vaccinated with VAKSIMUNE® IBD M+ maintained strong immune competence and developed a healthy antibody response against Newcastle Disease, ensuring complete protection without compromising overall flock health.

vaksindo